SN1 N Stock Overview Develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Smith & Nephew plc Competitors Price History & Performance
Summary of share price highs, lows and changes for Smith & Nephew Historical stock prices Current Share Price UK£290.15 52 Week High UK£290.15 52 Week Low UK£199.78 Beta 0.69 1 Month Change 0% 3 Month Change n/a 1 Year Change n/a 3 Year Change n/a 5 Year Change n/a Change since IPO -34.13%
Recent News & Updates
Smith+Nephew Introduces CORIOGRAPH Pre-Op Planning and Modeling Services for Total Hip Arthroplasty Dec 19
Smith & Nephew plc Provides Earnings Guidance for the Full Year 2024 and for 2025 Nov 02
Smith & Nephew plc to Report Fiscal Year 2024 Results on Feb 25, 2025 Oct 31
Smith+Nephew Announces LEGION Hinged Knee System Now Available in the United States with Proprietary OXINIUM (Oxidized Zirconium) Oct 02
Smith+Nephew Announces Board and Committee Changes Sep 27
High number of new directors Sep 18 See more updates
Smith+Nephew Introduces CORIOGRAPH Pre-Op Planning and Modeling Services for Total Hip Arthroplasty Dec 19
Smith & Nephew plc Provides Earnings Guidance for the Full Year 2024 and for 2025 Nov 02
Smith & Nephew plc to Report Fiscal Year 2024 Results on Feb 25, 2025 Oct 31
Smith+Nephew Announces LEGION Hinged Knee System Now Available in the United States with Proprietary OXINIUM (Oxidized Zirconium) Oct 02
Smith+Nephew Announces Board and Committee Changes Sep 27
High number of new directors Sep 18 Smith & Nephew plc Provides Revenue Guidance for the Second Half and Reaffirms Earnings Guidance for the Year 2024
Smith+Nephew Announces 510(K) Clearance of New Catalysystem Primary Hip System Jul 17 Cevian Capital II GP Limited acquired 5.02% stake in Smith & Nephew plc (LSE:SN.). Jul 05
High number of new directors May 16
Smith & Nephew plc Announces Final Dividend of the Year Ended 31 December 2023, Payable on May 22, 2024 May 10
Smith & Nephew plc to Report First Half, 2024 Results on Aug 01, 2024 May 01
High number of new directors Apr 12
Smith+Nephew Introduces the RENASYS EDGE Negative Pressure Wound Therapy System Apr 02 Smith & Nephew plc Announces Board Changes
Upcoming dividend of US$0.23 per share Mar 21
New minor risk - Earnings quality Mar 13
Full year 2023 earnings released: EPS: US$0.30 (vs US$0.26 in FY 2022) Mar 12
High number of new directors Mar 12
Smith & Nephew plc, Annual General Meeting, May 01, 2024 Mar 12 Smith & Nephew plc Recommends Final Dividend for 2023, Payable on May 22, 2024 Smith+Nephew Announces Commercial Launch of Its Aetos Shoulder System for Anatomic and Reverse Shoulder Replacement At Aaos 2024 Annual Meeting
Smith & Nephew plc Announces Standout Results for Its Regeneten Bioinductive Implant from A Recently Completed Randomized Controlled Trial Jan 11
Smith & Nephew plc (LSE:SN.) acquired CartiHeal (2009) Ltd. Jan 10
Smith+Nephew Announces Board Changes Dec 07
Smith+Nephew Announces Board Changes Dec 06
Smith & Nephew plc (LSE:SN.) entered into a definitive agreement to acquire CartiHeal (2009) Ltd. for $330 million. Nov 24
Smith & Nephew plc (LSE:SN.) entered into a definitive agreement to acquire CartiHeal (2009) Ltd. for $330 million. Nov 23
High number of new directors Nov 08
Smith & Nephew plc Provides Earning Guidance for Full Year 2023 Nov 04
Smith & Nephew plc Announces Appointment of John Rogers as CFO Nov 02
Smith & Nephew plc Announces Interim Dividend for 2023, Payable 1 November 2023 Oct 21
Smith & Nephew plc Announces Board and Committee Changes Sep 14
Smith & Nephew plc Increases Revenue Guidance for 2023 Aug 04 Smith & Nephew plc Announces Step Down of Anne-Françoise Nesmes as Chief Financial Officer Aug 03
Smith+Nephew Announces 510(K) Clearance of its AETOS Shoulder System Jun 13
High number of new directors Feb 23 Smith & Nephew plc, Annual General Meeting, Apr 26, 2023
High number of new directors Jan 31
Smith & Nephew plc to Report Fiscal Year 2022 Results on Feb 21, 2023 Nov 04
Smith & Nephew plc Announces Revenue Guidance for 2022 Nov 03
Smith+Nephew Expands Procedural Innovation with Introduction of JOURNEY(TM) II ROX(TM) Total Knee Solution Nov 02
Smith+Nephew First to Market with Revision Knee Indication on Robotics Platform Sep 27
Smith+Nephew Launches OR3O ™ Dual Mobility System in Japan for Use in Primary and Revision Hip Arthroplasty Sep 20
Smith+Nephew Announces New Data Furthering a Number of Published Studies Supporting the Use of Its REGENETEN Bioinductive Implant in Rotator Cuff Repair Sep 15 Smith & Nephew plc to Report Q2, 2023 Results on Aug 03, 2023
Smith & Nephew plc Announces Executive Changes Sep 01
First half 2022 earnings released Jul 28 Smith & Nephew plc Provides Revenue Guidance for the Second Half and Full Year of 2022
Investor sentiment deteriorated over the past week Jul 23
Now 23% undervalued Jul 21
Smith+Nephew Launches Clinical Support App to Help Reduce Practice Variation in Wound Care Jul 12
Smith & Nephew plc Announces Executive Changes Jun 21
Smith & Nephew plc Announces Executive Changes Jun 20
Smith+Nephew Announces First Total Hip Replacement Cases on its CORI Surgical System Using RI.HIP Modeler and RI.HIP Navigation Jun 09 Shareholder Returns SN1 N MX Medical Equipment MX Market 7D 0% 0% 0% 1Y n/a 0% 0%
See full shareholder returns
Return vs Market: Insufficient data to determine how SN1 N performed against the MX Market .
Price Volatility Is SN1 N's price volatile compared to industry and market? SN1 N volatility SN1 N Average Weekly Movement n/a Medical Equipment Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in MX Market 0% 10% least volatile stocks in MX Market 0%
Stable Share Price: SN1 N's share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine SN1 N's volatility change over the past year.
About the Company Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Show more Smith & Nephew plc Fundamentals Summary How do Smith & Nephew's earnings and revenue compare to its market cap? SN1 N fundamental statistics Market cap Mex$221.30b Earnings (TTM ) Mex$6.15b Revenue (TTM ) Mex$113.67b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SN1 N income statement (TTM ) Revenue US$5.64b Cost of Revenue US$1.67b Gross Profit US$3.97b Other Expenses US$3.66b Earnings US$305.00m
Last Reported Earnings
Jun 29, 2024
Next Earnings Date
Feb 25, 2025
Earnings per share (EPS) 0.35 Gross Margin 70.33% Net Profit Margin 5.41% Debt/Equity Ratio 66.7%
How did SN1 N perform over the long term?
See historical performance and comparison Dividends
3.0% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/15 13:07 End of Day Share Price 2024/09/17 00:00 Earnings 2024/06/29 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Smith & Nephew plc is covered by 57 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kamla Singh AlphaValue Christoph Gubler Bank Vontobel AG Hassan Al-Wakeel Barclays
Show 54 more analysts 